Home・Список акций・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

116.2 0.79

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

112.03

Макс.

117.14

Ключевые показатели
By Trading Economics
Доход	-8.1M -56M
Продажи	2.9M 60M
Прибыль на акцию	-0.83
Рентабельность продаж	-92.559
Сотрудники	414
EBITDA	-7.6M -50M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+23.37% upside

Дивиденды
By Acuity
Следующий отчет о доходах	3 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	1.2B 7.1B
Предыдущая цена открытия	115.41
Предыдущая цена закрытия	116.2

Новостные настроения

By Acuity

60%

40%

274 / 340 Рейтинг в Healthcare

Rhythm Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 авг. 2026 г., 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

7 авг. 2026 г., 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

6 авг. 2026 г., 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

5 авг. 2026 г., 20:02 UTC

Event

News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

4 авг. 2026 г., 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

3 авг. 2026 г., 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 июл. 2026 г., 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 июл. 2026 г., 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 июл. 2026 г., 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 июл. 2026 г., 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

27 июл. 2026 г., 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

24 июл. 2026 г., 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

21 июл. 2026 г., 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

20 июл. 2026 г., 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Сравнение c конкурентами

Изменение цены

Rhythm Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

23.37% рост

Прогноз на 12 месяцев

Средняя 142.47 USD 23.37%

Максимум 160 USD

Минимум 105 USD

Основано на мнении 15 аналитиков Wall Street, спрогнозировавших целевые цены для Rhythm Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

15 ratings

Покупка

Удержание

Продажа

Основано на мнении 15 аналитиков, присваивавших рейтинги акциям Rhythm Pharmaceuticals Inc – Данные за последние 3 месяца.

Настроения

By Acuity

274 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.